PFAS Modulate Osmotic Signaling Independent of Gravimetric Changes in the Rat Uterus

Overview

Journal Toxics

Date 2024 Mar 27

PMID 38535903

Authors

Aaron Dixon

Evelyn G Rowan

Allison N Yackley

Erin P Hines

Affiliations

Soon will be listed here.

Abstract

Various PFAS have been identified as potential endocrine-disrupting chemicals due to estrogen receptor activation, impacts on puberty timing, or impacts on hormonally sensitive endpoints in fish. This study screened multiple PFAS in the rat uterotrophic assay to determine potential estrogenic effects on the uterus with PFAS exposure. This study also explored PFAS-dependent uterine signaling with an osmotic stress mRNA gene expression array. Briefly, Sprague-Dawley rats (26-39 days old) were ovariectomized, and uterine tissue was allowed to regress for a 3-week period of recovery. Animals were then exposed daily via oral gavage to PFAS for 4 days, and then uterine weight was determined. In contrast to the positive control estrogens, the PFAS tested (4:2, 6:2, and 8:2FTOH; perfluorooctanesulfonamide (PFOSA), perfluorononanoic acid (PFNA), perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS), nafion byproduct 2 (NBP2), 1H,1H,8H,8H-perfluorooctane-1,8-diol (FC8-diol) and 1H,1H,10H,10H-perfluorodecane-1,10-diol (FC10-diol)) caused no significant changes in the uterine weight. Hormonally active compounds can act as carcinogens, and because earlier rodent work has demonstrated that chronic PFOA exposure is associated with increased risk of uterine cancer, uterine mRNA gene expression was explored with an osmotic stress RT-qPCR array. PFAS exposure significantly upregulated multiple genes across the array, with PFOSA being the compound most similar to the reference estrogens (estradiol benzoate and ethinyl estradiol) in its expression pattern. Also, across all PFAS, pathway analysis revealed that the paxillin pathway, a pathway important in tumor suppressor gene SHP-2 signaling, was significantly upregulated with PFAS exposure. These results demonstrate that in vitro estrogen screens or impacts in fish may show different responses from direct impacts on mammalian uterine weight as assessed with the uterotrophic assay. This study also builds out new mechanisms that may contribute to understanding of carcinogenic changes seen in the uterus after PFAS exposure.

References

Zhou W, Zhang L, Tong C, Fang F, Zhao S, Tian Y . Plasma Perfluoroalkyl and Polyfluoroalkyl Substances Concentration and Menstrual Cycle Characteristics in Preconception Women. Environ Health Perspect. 2017; 125(6):067012. PMC: 5743639. DOI: 10.1289/EHP1203. View

Li J, Cao H, Feng H, Xue Q, Zhang A, Fu J . Evaluation of the Estrogenic/Antiestrogenic Activities of Perfluoroalkyl Substances and Their Interactions with the Human Estrogen Receptor by Combining Assays and Modeling. Environ Sci Technol. 2020; 54(22):14514-14524. DOI: 10.1021/acs.est.0c03468. View

Villeneuve D, Blackwell B, Cavallin J, Collins J, Hoang J, Hofer R . Verification of In Vivo Estrogenic Activity for Four Per- and Polyfluoroalkyl Substances (PFAS) Identified as Estrogen Receptor Agonists via New Approach Methodologies. Environ Sci Technol. 2023; 57(9):3794-3803. PMC: 10898820. DOI: 10.1021/acs.est.2c09315. View

Dhingra R, Darrow L, Klein M, Winquist A, Steenland K . Perfluorooctanoic acid exposure and natural menopause: A longitudinal study in a community cohort. Environ Res. 2016; 146:323-30. DOI: 10.1016/j.envres.2015.12.037. View

Dixon D, Reed C, Moore A, Gibbs-Flournoy E, Hines E, Wallace E . Histopathologic changes in the uterus, cervix and vagina of immature CD-1 mice exposed to low doses of perfluorooctanoic acid (PFOA) in a uterotrophic assay. Reprod Toxicol. 2011; 33(4):506-512. PMC: 3362692. DOI: 10.1016/j.reprotox.2011.10.011. View

Prokai L, Rahlouni F, Zaman K, Nguyen V, Prokai-Tatrai K . Proteomics Complementation of the Rat Uterotrophic Assay for Estrogenic Endocrine Disruptors: A Roadmap of Advancing High Resolution Mass Spectrometry-Based Shotgun Survey to Targeted Biomarker Quantifications. Int J Mol Sci. 2021; 22(4). PMC: 7914934. DOI: 10.3390/ijms22041686. View

Dazhi W, Jing D, Chunling R, Mi Z, Zhixuan X . Elevated SLC6A6 expression drives tumorigenesis and affects clinical outcomes in gastric cancer. Biomark Med. 2019; 13(2):95-104. DOI: 10.2217/bmm-2018-0256. View

Gui S, Qiao J, Xu K, Li Z, Chen Y, Wu K . Association between per- and polyfluoroalkyl substances exposure and risk of diabetes: a systematic review and meta-analysis. J Expo Sci Environ Epidemiol. 2022; 33(1):40-55. DOI: 10.1038/s41370-022-00464-3. View

Dunder L, Salihovic S, Elmstahl S, Lind P, Lind L . Associations between per- and polyfluoroalkyl substances (PFAS) and diabetes in two population-based cohort studies from Sweden. J Expo Sci Environ Epidemiol. 2023; 33(5):748-756. PMC: 10541316. DOI: 10.1038/s41370-023-00529-x. View

10.

Houck K, Patlewicz G, Richard A, Williams A, Shobair M, Smeltz M . Bioactivity profiling of per- and polyfluoroalkyl substances (PFAS) identifies potential toxicity pathways related to molecular structure. Toxicology. 2021; 457:152789. DOI: 10.1016/j.tox.2021.152789. View

11.

Pramod A, Foster J, Carvelli L, Henry L . SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol Aspects Med. 2013; 34(2-3):197-219. PMC: 3602807. DOI: 10.1016/j.mam.2012.07.002. View

12.

Ma Z, Liu X, Li F, Wang Y, Xu Y, Zhang M . Perfluorooctanoic acid induces human Ishikawa endometrial cancer cell migration and invasion through activation of ERK/mTOR signaling. Oncotarget. 2016; 7(41):66558-66568. PMC: 5341820. DOI: 10.18632/oncotarget.11684. View

13.

Wei Y, Liu Y, Wang J, Tao Y, Dai J . Toxicogenomic analysis of the hepatic effects of perfluorooctanoic acid on rare minnows (Gobiocypris rarus). Toxicol Appl Pharmacol. 2007; 226(3):285-97. DOI: 10.1016/j.taap.2007.09.023. View

14.

Conley J, Lambright C, Evans N, Medlock-Kakaley E, Dixon A, Hill D . Cumulative maternal and neonatal effects of combined exposure to a mixture of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) during pregnancy in the Sprague-Dawley rat. Environ Int. 2022; 170:107631. PMC: 9944680. DOI: 10.1016/j.envint.2022.107631. View

15.

Liu C, Du Y, Zhou B . Evaluation of estrogenic activities and mechanism of action of perfluorinated chemicals determined by vitellogenin induction in primary cultured tilapia hepatocytes. Aquat Toxicol. 2007; 85(4):267-77. DOI: 10.1016/j.aquatox.2007.09.009. View

16.

Campbell S, Raza M, Pollack A . Perfluoroalkyl substances and endometriosis in US women in NHANES 2003-2006. Reprod Toxicol. 2016; 65:230-235. DOI: 10.1016/j.reprotox.2016.08.009. View

17.

Das K, Grey B, Rosen M, Wood C, Tatum-Gibbs K, Zehr R . Developmental toxicity of perfluorononanoic acid in mice. Reprod Toxicol. 2014; 51:133-44. DOI: 10.1016/j.reprotox.2014.12.012. View

18.

Evans N, Conley J, Cardon M, Hartig P, Medlock-Kakaley E, Gray Jr L . In vitro activity of a panel of per- and polyfluoroalkyl substances (PFAS), fatty acids, and pharmaceuticals in peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, and estrogen receptor assays. Toxicol Appl Pharmacol. 2022; 449:116136. PMC: 9341220. DOI: 10.1016/j.taap.2022.116136. View

19.

Florentin A, Deblonde T, Diguio N, Hautemaniere A, Hartemann P . Impacts of two perfluorinated compounds (PFOS and PFOA) on human hepatoma cells: cytotoxicity but no genotoxicity?. Int J Hyg Environ Health. 2011; 214(6):493-9. DOI: 10.1016/j.ijheh.2011.05.010. View

20.

Zahm S, Bonde J, Chiu W, Hoppin J, Kanno J, Abdallah M . Carcinogenicity of perfluorooctanoic acid and perfluorooctanesulfonic acid. Lancet Oncol. 2023; 25(1):16-17. DOI: 10.1016/S1470-2045(23)00622-8. View